Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Redington MD and Group CEO V.S. Hariharan Appointed to GTDC Executive Committee12.5.2026 15:00:00 CEST | Press release
GTDC appointed V.S. Hariharan, Managing Director and Group CEO of the Redington Group, to its Executive Committee (EC) to guide strategy and provide operational oversight. The EC advances the organization's mission to educate, advocate, and influence the tech industry on the evolving role of IT distribution worldwide. Mr. Hariharan leads Redington's $11.8 billion distribution and supply chain business across 40 markets. Redington continues to strengthen its role as a Technology Orchestrator, enabling seamless connections across the ecosystem to Unlock Next opportunities for partners. TAMPA, FL / ACCESS Newswire / May 12, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, named V.S. Hariharan, Managing Director and Group CEO of Redington Limited, to its Executive Committee. The committee provides operational oversight and helps guide GTDC's long-term strategy, advancing the organization's mission to strengthen distributio
Braiin Advances Proposed Acquisition of Home.cc with Valuation and Growth-Capital Components Totaling Approximately A$73 Million to Build AI-Native LivTech Platform for Residential Lifecycle Services, Targeting the $3+ Trillion Global Residential Lifecycle Services Market12.5.2026 14:15:00 CEST | Press release
Proposed acquisition would combine Home's embedded residential distribution, payments infrastructure and household-services platform with Braiin's AI, CXaaS and PropTech ecosystem MELBOURNE, AU AND LONDON, UK / ACCESS Newswire / May 12, 2026 / Braiin Limited (NASDAQ:BRAI) ("Braiin" or the "Company"), a global AI platform company delivering automation and predictive analytics across precision agriculture, customer experience and property technology, today announced that it has entered into a non-binding term sheet to advance its proposed acquisition of Home.cc ("Home"), a Living Technology ("LivTech") platform focused on embedded residential distribution, household service activation, payments and connected living infrastructure. Under the proposed structure, Braiin would acquire a 50.1% majority interest in Cumbria Capital Ltd, the parent company of Home.cc, through a share purchase to be satisfied by the issuance of Braiin equity securities. The non-binding term sheet contemplates a p
Polaris Renewable Energy Announces Approval of SO1 Agreement by FOMB12.5.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 12, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that, on May 8, 2026, the Financial Oversight and Management Board of Puerto Rico ("FOMB") approved the Battery Energy Storage System ("BESS") Standard Offer Agreement ("SO1 Agreement"). The approval of the FOMB completes the three-steps approval process for the SO1 Agreement, following prior regulatory approvals obtained from the Puerto Rico Energy Bureau ("PREB") and the Governing Board of the Puerto Rico Electric Power Authority ("PREPA"). The SO1 Agreement is intended to be executed between PREPA and Polaris Power US, Inc ("PPUS"), a wholly owned subsidiary of Polaris. The SO1 Agreement forms part of the Puerto Rico Accelerated Storage Addition Program ("ASAP"), a strategic initiative aimed at strengthening grid reliability across the island through the deployment of utility-scale BESS co-located with existing generation facilities. Under this
Elixir Technologies Unveils Elixir Muse: The AI Writing Assistant Built for Total Data Privacy12.5.2026 13:00:00 CEST | Press release
Elixir's new writing assistant product delivers AI-powered drafting, revision, translation, validation, tone of voice and sentiment analysis, and compliance analysis - without storing, harvesting or training on user data. OJAI, CA / ACCESS Newswire / May 12, 2026 / Elixir Technologies today introduced Elixir Muse™, a privacy-first AI writing assistant that significantly minimizes the workload involved in drafting, editing, proofreading and translating text. Powered by Elixir Ai, the company's proprietary AI technology, Elixir Muse™ assists both writers and content creators improve the quality, clarity and consistency of their written content through advanced AI features - all while safeguarding the privacy of user data. Elixir Muse™ introduces a fundamentally different approach to AI-assisted document iteration: one where privacy and control are prioritized from the start, rather than being an afterthought. With user-friendly writing features and proven use cases, the product functions
Dubai Health and AGFA HealthCare Mark 20 Years of Collaboration Supporting Dubai's Healthcare System12.5.2026 11:30:00 CEST | Press release
Dubai Health and AGFA HealthCare have marked 20 years of collaboration supporting Dubai's healthcare system, reflecting a shared commitment to advancing integrated, patient-centered care. DUBAI, AE / ACCESS Newswire / May 12, 2026 / Over the past two decades, AGFA HealthCare has supported Dubai's healthcare system - most recently contributing to Dubai Health's integrated academic health system across care, learning, and research through a shared digital foundation. It enables clinicians access to critical information while maintaining data security, operational continuity, and patient confidentiality, and supports large-scale screening services in high-volume settings. The partnership has progressed from digitizing diagnostic imaging into a comprehensive enterprise imaging, analytics, and AI ecosystem that supports multiple clinical specialties, leadership decision-making, and population-scale healthcare services across Dubai Health's expanding network. Atif Al Braiki, Chief Digital an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom